Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium‐Glucose Cotransporter 2 Inhibitors

Approximately one quarter of ACEi users discontinued their therapy within 1 year of SGLT2i initiation. We found that patient demographics, use of other medications, and clinical history were associated with ACEi discontinuation. These findings highlight the need for individualized strategies to support persistence with cardioprotective therapies in T2D care.